Long-term safety and efficacy of combined percutaneous LAA and PFO/ASD closure: a single-center experience (LAAC combined PFO/ASD closure)

References

• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983–988.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18:1609–1678.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
   PubMed Web of Science ®Google Scholar
• Reddy VY, Akehurst RL, Armstrong SO, et al. Time to cost-effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAA closure. J Am Coll Cardiol. 2015;66:2728–2739.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–2747.
   PubMed Web of Science ®Google Scholar
• Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. J Am Coll Cardiol. 2018;71:2335–2342.
   PubMed Web of Science ®Google Scholar
• Riaz H, Khan MS, Schenone AL, et al. Transcatheter closure of patent foramen ovale following cryptogenic stroke: an updated meta-analysis of randomized controlled trials. Am Heart J. 2018;199:44–50.
   PubMed Web of Science ®Google Scholar
• Ahmad Y, Howard JP, Arnold A, et al. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials. Eur Heart J. 2018;39:1638–1649.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. focused update of the ESC Guide -lines for the management of atrial fibrillation: anupdate of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385–1413.
   PubMed Web of Science ®Google Scholar
• Yue L, Zhai YN, Wei LQ. Which technique is better for detection of right-to-left shunt in patients with patent foramen ovale: comparing contrast transthoracic echocardiography with contrast transesophageal echocardiography. Echocardiography. 2014;31:1050–1055.
   PubMed Web of Science ®Google Scholar
• Xue X, Jiang L, Duenninger E, et al. Impact of chronic kidney disease on Watchman implantation: experience with 300 consecutive left atrial appendage closures at a single center. Heart Vessels. 2018:33(9):1068-1075.
   Web of Science ®Google Scholar
• Jiang L, Duenninger E, Muenzel M, et al. Percutaneous left atrial appendage closure with complex anatomy by using the staged ‘kissing-Watchman‘ technology with double devices. Int J Cardiol. 2018;265:58–61.
   PubMed Web of Science ®Google Scholar
• Dehghani H, Boyle AJ. Percutaneous device closure of secundum atrial septal defect in older adults. Am J Cardiovasc Dis. 2012;2:133–142.
   PubMedGoogle Scholar
• Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010;31:2915–2957.
   PubMed Web of Science ®Google Scholar
• Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA guidelines for the management of adults with congenital heart disease: a report of the American college of cardiology/American heart association task force on practice guidelines (Writing committee to develop guidelines on the management of adults with congenital heart disease). Developed in collaboration with the American society of echocardiography, heart rhythm society, international society for adult congenital heart disease, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol. 2008;52:e143–263.
   PubMed Web of Science ®Google Scholar
• Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59:17–20.
   PubMed Web of Science ®Google Scholar
• Handke M, Harloff A, Olschewski M, et al. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357:2262–2268.
   PubMed Web of Science ®Google Scholar
• Bridges ND, Hellenbrand W, Latson L, et al. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation. 1992;86:1902–1908.
   PubMed Web of Science ®Google Scholar
• Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368:1092–1100.
   PubMed Web of Science ®Google Scholar
• Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368:1083–1091.
   PubMed Web of Science ®Google Scholar
• Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991–999.
   PubMed Web of Science ®Google Scholar
• Sa M, Lap ON, Nascimento G, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke: meta-analysis of five randomized controlled trials with 3440 patients. Braz J Cardiovasc Surg. 2018;33:89–98.
   PubMed Web of Science ®Google Scholar
• Kheiri B, Abdalla A, Osman M, et al. Patent foramen ovale closure versus medical therapy after cryptogenic stroke: an updated meta-analysis of all randomized clinical trials. Cardiol J. 20182019;26(1):47-55.
   PubMed Web of Science ®Google Scholar
• Darmoch F, Al-Khadra Y, Soud M, et al. Transcatheter closure of patent foramen ovale versus medical therapy after cryptogenic stroke: a meta-analysis of randomized controlled trials. Cerebrovasc Dis. 2018;45:162–169.
   PubMed Web of Science ®Google Scholar
• He L, Cheng GS, Du YJ, et al. Multidisciplinary assessment of PFO with substantial right-to-left shunting and medium-term follow-up after PFO device closure: A single-center experience. J Interv Cardiol. 2017;30:362–367.
   PubMed Web of Science ®Google Scholar
• Koermendy D, Nietlispach F, Shakir S, et al. Amplatzer left atrial appendage occlusion through a patent foramen ovale. Catheter Cardiovasc Interv. 2014;84:1190–1196.
   PubMed Web of Science ®Google Scholar
• Gafoor S, Franke J, Boehm P, et al. Leaving no hole unclosed: left atrial appendage occlusion in patients having closure of patent foramen ovale or atrial septal defect. J Interv Cardiol. 2014;27:414–422.
   PubMed Web of Science ®Google Scholar
• De Rosa S, Sievert H, Sabatino J, et al. Percutaneous closure versus medical treatment in stroke patients with patent foramen ovale: a systematic review and meta-analysis. Ann Intern Med. 2018;168:343–350.
   PubMed Web of Science ®Google Scholar
• Shah R, Nayyar M, Jovin IS, et al. Device closure versus medical therapy alone for patent foramen ovale in patients with cryptogenic stroke: a systematic review and meta-analysis. Ann Intern Med. 2018;168:335–342.
   PubMed Web of Science ®Google Scholar